Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment

PURPOSE: Hypertension is a mechanism-based toxicity of sorafenib and other cancer therapeutics that inhibit the vascular endothelial growth factor (VEGF) signaling pathway (VSP). This prospective, single center, cohort study characterized ambulatory blood pressure (BP) monitoring (ABPM) as an early...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Maitland, Michael L., Kasza, Kristen E., Karrison, Theodore, Moshier, Kristin, Sit, Laura, Black, Henry R., Undevia, Samir D., Stadler, Walter M., Elliott, William J., Ratain, Mark J.
Format: Artigo
Idioma:Inglês
Publicat: 2009
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2756980/
https://ncbi.nlm.nih.gov/pubmed/19773379
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-09-0058
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars